Drug Profile
IkT 1427
Alternative Names: IkT-01427; IkT-1427Latest Information Update: 22 Jun 2022
Price :
$50
*
At a glance
- Originator Inhibikase Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Progressive multifocal leukoencephalopathy
Most Recent Events
- 22 Jun 2022 IkT 1427 is still in preclinical development for Progressive multifocal leukoencephalopathy in USA (Inhibikase Therapeutics pipeline, June 2022)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Progressive multifocal leukoencephalopathy in USA (PO)
- 12 Nov 2019 IkT 1427 is still in preclinical trials for Progressive multifocal leukoencephalopathy in USA (Inhibikase Therapeutics pipeline, November 2019)